Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TuHURA Biosciences, Inc./NV (HURA)

TuHURA Biosciences draws additional $650,000 under $50 million Parkview loan facility

Neutral Impact 2 of 5 financing Written later

TuHURA Biosciences borrowed an additional $650,000 on October 9, 2026, under a revolving credit facility with Parkview Holdings One LLC, as disclosed in a Form 8-K filed October 16, 2026. The company said it expects to use the funds for general corporate purposes, and the draw is small relative to the $50 million maximum availability under the facility.

Key points

  • Draw of $650,000 received and borrowed on October 9, 2026
  • Revolving credit facility under Loan Agreement dated April 21, 2026, with a maximum loan availability of $50 million
  • Facility matures April 21, 2031; the company expects to use funds for general corporate purposes
  • Filing notes risks including potential conflicts of interest from the loan with an affiliate of the largest stockholder

The filing

CompanyTuHURA Biosciences, Inc./NV (HURA)
Form8-K, current report
Filed with the SECOct 16, 2026, 5:00 PM ET
Accession number0001193125-26-424228

Items reported: 2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.